Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2013

View Archived Issues

Novel aminoglycoside antibiotic shows anti-MRSA activity with reduced nephrotoxicity

CETP inhibitors for the treatment of atherosclerosis

Smallpox vaccine CJ-50300 safe in phase III trial

Novan compares activity of Nitricil compounds against Staphylococcus aureus

Acacia Pharma initiates phase III studies of APD-421 for PONV

Regado Biosciences begins phase III trial of pegnivacogin/anivamersen

PeptiDream licenses PDPS technology to Bristol-Myers Squibb

AGE receptors identified in human osteoarthritic cartilage

Agenus reports follow-on phase II data for brain cancer vaccine

Third review also recommends PreSERVE AMI study continuation

Repros Therapeutics reports Androxal study data

BioCryst awarded NIAID contract to combat Marburg virus hemorrhagic fever

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Profectus BioSciences begins phase I trial of HIV plasmid DNA vaccine

H3 Biomedicine and Selvita establish strategic collaboration in oncology

Compugen reports data on immune checkpoint protein CGEN-15049

Rottapharm patents novel orexin OX1 receptor antagonists

FORMA Therapeutics and Genentech disclose Nampt inhibitors

PIQUR Therapeutics plans phase I study of PQR-309

Takeda designs series of MetAP 2 inhibitors

Allergan synthesizes series of chemokine CCR2 receptor antagonists

ChemoCentryx regains rights to vercirnon from GlaxoSmithKline

Mitsubishi Tanabe Pharma acquires Medicago

CE mark granted to Abbott's FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...